- Sections
- C - Chimiemétallurgie
- C07D - Composés hétérocycliques
- C07D 249/04 - Triazoles-1, 2, 3Triazoles-1, 2, 3 hydrogénés
Détention brevets de la classe C07D 249/04
Brevets de cette classe: 933
Historique des publications depuis 10 ans
|
62
|
55
|
49
|
65
|
62
|
51
|
69
|
53
|
49
|
37
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Theravance Biopharma R&D IP, LLC | 362 |
26 |
| Eonhf, Inc. | 45 |
21 |
| The Johns Hopkins University | 5887 |
17 |
| The Regents of the University of California | 20778 |
14 |
| Modernatx, Inc. | 1292 |
13 |
| Yale University | 2543 |
13 |
| Bristol-myers Squibb Company | 4751 |
10 |
| Sigilon Therapeutics, Inc. | 112 |
9 |
| Merck Sharp & Dohme LLC | 3736 |
9 |
| Siemens Medical Solutions USA, Inc. | 1468 |
8 |
| Astex Therapeutics Limited | 207 |
8 |
| Emory University | 1723 |
8 |
| The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth, Near Dublin | 178 |
8 |
| The University of Queensland | 654 |
8 |
| Novartis AG | 10251 |
7 |
| Centre National de La Recherche Scientifique | 11026 |
7 |
| ABA Chemicals Corporation | 24 |
7 |
| Nippon Soda Co., Ltd. | 882 |
7 |
| The Scripps Research Institute | 1340 |
7 |
| Boehringer Ingelheim International GmbH | 4493 |
6 |
| Autres propriétaires | 720 |